Search

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors
Community Letter: Update SRP-5051 Program
Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments
Strategic Partnerships
Sarepta Therapeutics Announces Recipients of LGMD Grant Awards for 2024; Program Supports Early Genetic Testing and Awareness
Sarepta Therapeutics anuncia a los destinatarios de las subvenciones de 2024 para LGMD; el programa apoya las pruebas genéticas tempranas y la concientización
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)